Genmab A/S (NASDAQ:GMAB) Stake Decreased by Natixis Advisors LLC

Natixis Advisors LLC trimmed its holdings in Genmab A/S (NASDAQ:GMAB) by 0.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 205,769 shares of the company’s stock after selling 794 shares during the quarter. Natixis Advisors LLC’s holdings in Genmab A/S were worth $4,294,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in GMAB. Charles Schwab Investment Management Inc. grew its stake in shares of Genmab A/S by 94.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock worth $636,000 after purchasing an additional 12,654 shares in the last quarter. AIMZ Investment Advisors LLC bought a new position in Genmab A/S in the 4th quarter valued at about $3,525,000. HighTower Advisors LLC acquired a new position in Genmab A/S during the 3rd quarter valued at about $273,000. Verition Fund Management LLC bought a new stake in shares of Genmab A/S during the 3rd quarter worth about $709,000. Finally, FMR LLC lifted its stake in shares of Genmab A/S by 13.5% in the 3rd quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after acquiring an additional 33,076 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Down 0.4 %

NASDAQ:GMAB opened at $19.76 on Friday. The stock has a fifty day simple moving average of $21.04 and a 200 day simple moving average of $22.19. The firm has a market capitalization of $13.08 billion, a price-to-earnings ratio of 11.36, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. Genmab A/S has a 1-year low of $18.64 and a 1-year high of $31.02.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Equities analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GMAB has been the topic of a number of research analyst reports. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a research note on Thursday, February 13th. Truist Financial lowered their price target on Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Thursday, January 23rd. William Blair raised Genmab A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 11th. Finally, Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Four analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $41.33.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.